-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
About 20% of patients with SARS-CoV-2 infection require hospitalization for pneumonia ( COVID-19
Infection with COVID-19
Several circulating biomarkers can reflect lung epithelial and endothelial injury
Blood vessel
We hypothesized that severe COVID-19 damages epithelial and/or endothelial lung cells and that this damage persists in patients with reduced DLCO after discharge
Study Design :
Research designThis prospective observational study included 215 adults hospitalized at our institution with PCR-confirmed COVID-19 pneumonia between May 2020 and November 2020 and studied 6 months after discharge
Research result:
Research result:At 6-month follow-up, 52% of patients remained symptomatic, mainly dyspnea (26%) and fatigue (18%)
Epithelial and Endothelial Biomarkers
Epithelial and Endothelial BiomarkersCirculating levels of epithelial (SP-A, SP-D, SLPI) and endothelial (sICAM-1 and angiopoietin-2) markers were significantly elevated in patients with decreased DLCO 6 months after discharge, especially in severe DLCO lower
high blood pressure diabetes
This study shows that 6 months after discharge, decreased DLCO is common in COVID-19 survivors, age over 60 years and the need for mechanical ventilation are significant risk factors, and these patients have elevated systemic levels of pulmonary epithelial circulation markers and endothelial damage
Collectively, these observations suggest that epithelial and endothelial lung damage persists for at least 6 months after discharge in severe COVID-19 patients
references:
Sibila O.
Sibila O.
Elevated plasma levels of epithelial and endothelial cell markers in COVID-19 survivors with reduced lung diffusing capacity six months after hospital discharge.
Respir Res.
2022 Feb 21;23(1):37.
doi: 10.
1186/s12931-022- 01955-5.
PMID: 35189887.
Elevated plasma levels of epithelial and endothelial cell markers in COVID-19 survivors with reduced lung diffusing capacity six months after hospital discharge.
Leave a comment here
